Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 7.1% Today

What is Zoetis Inc. Class A?

Zoetis (ZTS) is a leading global animal health company that develops and produces medicine and vaccinations for pets and livestock. The company has been experiencing growth in its companion animal product sales.

Why is Zoetis Inc. Class A going down?

ZTS stock is down 7.1% on Feb 13, 2025 17:42

• Despite exceeding Q4 earnings and revenue estimates, Zoetis (ZTS) experienced a decrease in its stock price due to its 2025 guidance falling short of expectations.
• Investors appeared displeased with the projected revenue range of $9.225B-$9.375B for 2025, which was lower than market estimates.
• The market's response indicates that although the company performed well in the recent quarter, concerns regarding its future growth projections and guidance resulted in the decline.
• Emphasizing key metrics and Wall Street projections did not completely alleviate investor apprehensions about Zoetis' long-term prospects, contributing to the stock's downward trajectory.

ZTS Price Chart

ZTS Technical Analysis

ZTS News

Zoetis Drops As 2025 Guidance Falls Short Of Estimates - Zoetis ( NYSE:ZTS )

Zoetis Q4 adjusted EPS rose to $1.40, beating estimates of $1.34, with sales of $2.32B, up 5%. Organic operational growth hit 9%. 2025 guidance projects revenue of $9.225B-$9.375B, with organic operational growth of 6%-8%.

https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates

Zoetis ( ZTS ) Tops Q4 Earnings and Revenue Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 2.19% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2415168/zoetis-zts-tops-q4-earnings-and-revenue-estimates

Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?

ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.

https://www.zacks.com/stock/news/2412927/zoetis-gears-up-to-report-q4-earnings-whats-in-the-cards

Curious about Zoetis ( ZTS ) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

https://www.zacks.com/stock/news/2412652/curious-about-zoetis-zts-q4-performance-explore-wall-street-estimates-for-key-metrics

Trending Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 8.0% Today

Injective ($INJ) Crypto Forecast: Up 5.8% Today

Memecoin ($MEME) Crypto Forecast: Down 6.1% Today

Pepe ($PEPE) Crypto Forecast: Down 5.0% Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Zoetis Inc. Class A Price History

19.08.2024 - ZTS Stock was down 1.7%

• The bearish movement in ZTS stock today could be attributed to profit-taking by investors after a recent 15% rise in the stock price over the past 3 months.
• The mixed performance of ZTS compared to the overall market might have led some investors to reevaluate their positions in the stock.
• The comparison between ZTS and SDZNY for better value might have also influenced investor sentiment, potentially causing some to shift their investments away from ZTS.
• Despite the positive outlook for ZTS with its innovative products and business expansion efforts, short-term market dynamics and profit considerations could have driven the bearish movement in the stock today.

06.10.2024 - ZTS Stock was down 2.3%

• Despite reporting strong Q3 earnings and revenue beats, Zoetis' stock experienced a bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of sustained growth.
• The comparison with other value stocks like SDZNY might have influenced some investors to shift their positions, impacting Zoetis' stock price.
• Overall, the bearish movement could be a short-term correction in response to recent positive news, presenting a potential buying opportunity for investors bullish on Zoetis' long-term prospects.

04.11.2024 - ZTS Stock was down 0.1%

• The bearish movement in ZTS could be attributed to profit-taking by investors after a period of sustained growth in the stock.
• The bullish note on Autodesk and other companies may have diverted investor attention away from ZTS, leading to a lack of buying interest and contributing to the downward pressure on the stock.
• Analyst initiations on other companies might have overshadowed ZTS, causing a shift in focus and resulting in the bearish movement observed today.
• Overall, the market movement in ZTS could be a combination of internal profit-taking and external factors drawing investor interest elsewhere.

15.03.2024 - ZTS Stock was down 7.9%

• The bearish movement in ZTS stock today can be attributed to the following factors:
• Suggestions that arthritis drugs manufactured by Zoetis may be causing illnesses in pets, leading to concerns among investors.
• Investigations by multiple law firms into potential claims against Zoetis have created legal risks for the company and prompted investors to sell their positions.
• Despite recent developments, Zoetis' core business fundamentals remain strong, offering growth prospects. This could be seen as a value investment opportunity for investors as the stock price has decreased amid market uncertainty.

08.04.2024 - ZTS Stock was down 5.1%

• Despite strong Q1 earnings and revenue exceeding expectations, Zoetis (ZTS) experienced a bearish trend in the market.
• Investors may have engaged in profit-taking activities after a recent 6% stock price surge post-earnings announcement.
• Expectations of more positive guidance or outlook from Zoetis may have led to investor disappointment, resulting in a stock sell-off.
• A comparison with industry peers like Johnson & Johnson may have revealed areas where Zoetis needs to further distinguish itself to attract investor attention.

30.04.2024 - ZTS Stock was down 1.0%

• Zoetis (ZTS) stock showed a downward trend today.
• Concerns regarding the effects of arthritis medications on animals have impacted ZTS stock negatively.
• Ongoing examinations by legal entities and financial consultants concerning potential issues in Q1 have added to investor apprehension.
• The prevailing pessimism surrounding Zoetis possibly influenced the bearish market behavior witnessed today.

27.05.2024 - ZTS Stock was up 6.3%

• The bullish movement in ZTS today can be attributed to:
• The overall positive sentiment towards biotech and pharmaceutical stocks, emphasizing the growth potential and value of companies in these sectors.
• The increasing focus on healthcare and biotechnology sectors as investors potentially rotate away from tech stocks, leading to a surge in interest and investment in companies like Zoetis Inc.
• The mention of the Dog Vitamins Market growth potential indirectly benefiting companies like Zoetis Inc., which operates in the animal health industry and could see increased demand for its products in the future.

06.07.2024 - ZTS Stock was up 5.3%

• The company reported its financial results for the second quarter of 2024, exceeding estimates and raising its guidance for the full year 2024.
• Revenue for the second quarter of 2024 increased by 8% compared to the same period last year, showcasing strong operational growth.
• Analysts raised their target for Zoetis shares, reflecting a positive outlook on the company's performance and potential.
• Despite a declining market, Zoetis stock advanced, indicating investor confidence in the company's financial health and growth prospects.

06.07.2024 - ZTS Stock was up 5.1%

• Zoetis (ZTS) experienced a strong bullish movement today.
• The surge in stock price can be attributed to the company's impressive Q2 earnings performance, surpassing both earnings and revenue estimates.
• The positive market reaction was further fueled by Zoetis raising its outlook for 2024, indicating strong confidence in future performance.
• The beat-and-raise quarter showcased Zoetis' ability to capitalize on the growing demand for companion animal products, driving investor optimism and pushing the stock higher.

06.07.2024 - ZTS Stock was up 5.2%

• Zoetis reported better-than-expected second-quarter financial results and raised its 2024 guidance, instilling confidence in investors.
• The company beat earnings per share and revenue estimates for Q2 2024, driven by strong sales of companion animal products.
• The market reacted positively to Zoetis' "beat-and-raise" quarter, where the company exceeded expectations and provided an optimistic outlook for the future.
• Overall, the bullish movement in ZTS stock can be attributed to the company's solid performance and optimistic guidance, showcasing its resilience and growth potential in the animal health industry.

13.01.2025 - ZTS Stock was down 9.2%

• The bearish movement in ZTS stock today may be due to profit-taking by investors ahead of the company's upcoming Q4 earnings report. Despite positive performance metrics and anticipated earnings growth on Wall Street, market uncertainty could be causing this downward trend. Investors seem to be adopting a cautious approach, possibly concerned about meeting or surpassing high estimates.

13.01.2025 - ZTS Stock was down 7.1%

• Despite exceeding Q4 earnings and revenue estimates, Zoetis (ZTS) experienced a decrease in its stock price due to its 2025 guidance falling short of expectations.
• Investors appeared displeased with the projected revenue range of $9.225B-$9.375B for 2025, which was lower than market estimates.
• The market's response indicates that although the company performed well in the recent quarter, concerns regarding its future growth projections and guidance resulted in the decline.
• Emphasizing key metrics and Wall Street projections did not completely alleviate investor apprehensions about Zoetis' long-term prospects, contributing to the stock's downward trajectory.